Term Efficacy News Today

A randomized study published in 2022 showed the vaccine's efficacy in preventing urinary tract infections over 9 months.

January’s Dermatology Month in Review features 2 major FDA decisions, positive results on a new assessment tool, an evaluation of climate change’s impact on eczema, and more.

From adjunctive cariprazine for the treatment of major depressive disorder to a new app for prescribing antidepressants and antipsychotics, here are highlights from the week in Psychiatric Times.

This ACNP 2023 Annual Meeting poster covered a 26-week study on cariprazine as an adjunctive treatment to antidepressants in patients with major depressive disorder.

SEATTLE, Dec. 05, 2023 -- Adaptive Biotechnologies Corporation , a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to...

The 148-week study evaluated multiple domains of patients with psoriatic arthritis receiving risankizumab treatment, providing insights into patients' improvement over time.

Three ongoing, randomized, double-blind, multicenter Phase 3 studies demonstrated the long-term efficacy and safety profile of RINVOQ® in treating moderate to severe atopic dermatitis based on...

From the efficacy of adjunctive TMS for treatment-resistant major depression to a look at adult ADHD, here are highlights from the week in Psychiatric Times.

Investigators noted sustained improvement in depressive symptoms for up to 6.5 years.

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson will showcase data from its neuropsychiatry portfolio at Psych Congress 2023. The...